 The objective of this study is to estimate the median progression -free survival for patients receiving this regimen, along with the rate of complete response at 6 months, toxicities associated with this regimen, and laboratory correlates. Subjects will receive the ZevalinIbritumomab Tiuxetan therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression. 